Rockcliffe Labs Launches $75 Million Canadian Development Financing at $10 per Share, Reflecting $300 Million Post-Money Valuation; Executes License with a Canadian University for a Late-Stage Sepsis Biomarker–Based Program

Rockcliffe Labs Launches $75 Million Canadian Development Financing at $10 per Share, Reflecting $300 Million Post-Money Valuation; Executes License with a Canadian University for a Late-Stage Sepsis Biomarker–Based Program

TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Rockcliffe Labs Inc. (“Rockcliffe Labs” or the “Company”), a Canadian biotechnology venture creation platform, announces the launch of a $75 million non-brokered private placement in Canada (the “Offering”) at $10.00 per common share.…